NCT05674045View on ClinicalTrials.gov

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

January 6, 2022

Study Completion Date

September 26, 2022

Conditions

Stress Urinary Incontinence

Interventions

DRUG

EG017 3mg

EG017 3mg/day Oral administration for 12 weeks, once daily

DRUG

EG017 6mg

EG017 6mg/day Oral administration for 12 weeks, once daily

Trial Locations (1)

100000

People's Hospital of Peking University, Beijing

All Listed Sponsors

collaborator

Peking University People's Hospital

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY

NCT05674045 - A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence | Biotech Hunter | Biotech Hunter